Growth factor receptor-bound protein 10 (GRB10) is a critical adapter protein that acts as a key negative regulator of insulin receptor (INSR) and insulin-like growth factor 1 receptor (IGF1R) signaling pathways. Positioned at the intersection of metabolic regulation, oncology, and muscle hypertrophy, GRB10 represents an attractive but challenging intracellular target. Developing therapeutics against GRB10—ranging from small molecule inhibitors and PROTACs targeting its SH2/PH domains to RNA-based silencing strategies—requires highly characterized, sequence-verified molecular tools to validate target engagement and downstream pathway modulation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GRB10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRB10 Recombinant Protein (Full-Length & SH2 Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for biophysical binding assays. |
View GRB10 Products |
| Gene Delivery | GRB10 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View GRB10 Products |
| Benchmark Ab | Anti-GRB10 Recombinant Antibody Recombinant positive control for western blot, IP, and intracellular localization assays. |
View GRB10 Products |
| Validator | GRB10 siRNA Set For target knockdown verification and functional phenotypic rescue assays. |
View GRB10 Products |
| Related Target A | INSR (Insulin Receptor) Primary upstream receptor regulated by GRB10; critical for metabolic assay readouts. |
View INSR Products |
| Related Target B | IGF1R Upstream growth factor receptor; GRB10 binding modulates cell proliferation and survival. |
View IGF1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High homology within the Grb7/10/14 family leading to off-target binding | Recombinant GRB7, GRB10, and GRB14 proteins strictly sequence-verified and purity checked (>95%) for counter-screening |
| Intracellular localization requiring cell-based functional validation | High-titer Lentiviral particles optimized for stable cell line construction and target validation |
| Lack of reliable positive control reagents | Sequence-defined recombinant benchmark antibodies available for assay normalization |
| False positive siRNA-mediated phenotypes | Multi-sequence pooled siRNA sets validated for target knockdown specificity |
Live GRB10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development targeting GRB10 is gaining traction, particularly as structural biology advances our understanding of its multi-domain architecture (including the PH, BPS, and SH2 domains). While traditionally viewed as an "undruggable" intracellular adapter, the rise of targeted protein degradation (PROTACs) and RNA therapeutics has revitalized interest. Current R&D efforts are bifurcated: oncology programs aim to block GRB10-mediated feedback inhibition to overcome resistance to PI3K/mTOR inhibitors, while metabolic and regenerative medicine programs investigate GRB10 inhibition to enhance insulin sensitivity and promote muscle growth.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Small Molecules | Academic Institutes, Biotech Startups | Solid Tumors, Type 2 Diabetes | Binding kinetics on isolated SH2/PH domains (Need high-purity recombinant GRB10 domains) |
| RNA Interference (siRNA/ASO) | Metabolic-focused Biopharma | Obesity, Muscle Wasting (Sarcopenia) | In vitro knockdown efficiency validation (Need sequence-verified siRNA and Lentivirus) |
| Gene Therapy / Overexpression | Regenerative Medicine Groups | Metabolic Syndromes | Stable expression verification (Need high-titer Lentivirus and benchmark detection antibodies) |